About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance ...

The complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) DexCom had made material design changes to its G6 and G7 ...

DexCom (DXCM) stock ought to be included on your watchlist. Here is why – it is presently trading within the support range ...

Continuous glucose monitoring can identify unrecognized hyperglycemia and hypoglycemia in dialysis patients, challenging reliance on A1c for diabetes management.

DexCom (DXCM) is forecasting robust earnings growth of 19.2% per year and revenue growth of 11.8% per year. Both figures outpace the broader US market’s revenue growth forecast of 10.4%. Over the past ...

Dexcom Inc. executives may have thought a $30 million beat ... but investors seemed to feel tricked instead. The continuous glucose monitoring powerhouse saw its share price drop a frightening 17% in ...

The world's largest online retailer got a lift from its booming cloud computing business on Friday, Oct. 31, 2025, while a ...

Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) fell 6% in the afternoon session after investor ...

DexCom stock drops 15% despite strong Q3 and raised 2025 revenue outlook, as margin concerns and D7 product issues spark uncertainty for future growth. Read more here.

After dealing with a deployment problem with glucose monitors earlier this year, interim CEO Jake Leach said improving ...

DexCom was named a Barron’s stock pick in July. After DexCom shifted its focus to the Type 2 population last year, Type 1 ...

DexCom posts Q3 revenue of $1.21 billion, beating estimates and raising 2025 guidance as analysts expect strong sales and margin improvement ahead.